

# Therapy for diffuse astrocytic and oligodendroglial tumors in adults.

Guideline ID: 2598

Published: 2022 Feb 1

**American Society of Clinical Oncology (ASCO) | Society for Neuro-Oncology (SNO)**

*Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022 Feb 1;40(4):403-426. [109 references] [PubMed](#)*

[View Original Guideline](#)

## Overview

### Guideline Objective

To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults

### Patient Population

Adult people with glioma who have received maximal safe surgical resection

## Recommendations

### Recommendation Statements

Major interventions covered in this guideline include:

- Guidance on use of therapies (i.e., radiation therapy, chemotherapy, electric field therapy) for newly diagnosed and recurrent glioma, including optimal regimens, settings, and timing
- Role of *MGMT* promoter methylation status on choice of therapy
- Subpopulation considerations for choice of therapy

**Note:** Refer to the [original guideline](#) and [rapid recommendation update \(Apr 2025\)](#) for full recommendation statements.

## Evidence Rating Scheme

Refer to the original guideline documentation for more information.

## Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

## Related Content

## Supporting Documents

- [Data Supplement](#); 2022.
- [Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update](#); 2025 Apr 29.
  - [Data Supplement](#); 2025.

## Implementation Tools

- [Slide Set](#); 2021.
- [Visual Abstract](#); 2021.
- [ASCO-SNO Guideline Rapid Recommendation Update](#):

- [Clinical Insights](#); 2025 Apr 29.
- [Slide Set](#); 2025.
- [Summary of Recommendations Table](#); 2025.
- [Algorithm](#); 2025.
- [Visual Abstract](#); 2025.
- [Podcast: Interview with Guideline Co-Chair](#); 2025 Apr 29.

## Patient Education

- [Treating Brain and Spinal Cord Tumors in Adults](#).

**Note:** This patient information is intended to help patients better understand their health and their diagnosed disorders. Patients and their representatives should still consult with a licensed health care professional for evaluation of treatment options as well as answers to their personal medical questions.

## Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

# TRUST Scorecard

## Composition of Guideline Development Group (GDG)

Multidisciplinary GDG Members

Yes

Methodologist Involvement

Yes

Incorporation of Patient and Public Perspective



## Systematic Review of Evidence

Literature Search



Study Selection



Evidence Synthesis



## Foundations for Recommendations

Strength of Evidence Grade



Description of Benefits and Harms of Recommendations



Summary of Evidence Supporting Recommendations



Strength of Recommendations Rating



Clear Articulation of Recommendations



**Funding Source**

Yes

**Disclosure and Management of Financial Conflicts of Interests**



**External Review**



**Updating**

